HAYA Therapeutics raises €58.5M Series A round
8 May 2025· Lausanne, Switzerland· health, drug_discovery, biotech, ai, b2b
The funding will accelerate the clinical development of HAYA's lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure (initially focused on non-obstructive hypertrophic cardiomyopathy) and expand its RNA-guided regulatory genome pipeline development engine into other chronic and age-related diseases, including pulmonary fibrosis and obesity.
Investors
LeadSofinnova Partners
Also participating
Earlybird Venture CapitalSchroders CapitalAlexandria Venture Investments4see venturesApollo Health VenturesEli Lilly and CompanyATHOS+ND CapitalLifeLink VenturesLongview VenturesBERNINA Bioinvest
About HAYA Therapeutics
Stage
Series A
Headquarters
Lausanne, Switzerland
Founded
2017
Team Size
21–50
Sectors
healthdrug_discoverybiotechaib2b